Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies
References (151)
- et al.
Anticonvulsant effects of memantine and MK-801 in guinea pig hippocampal slices
Brain Research Bulletin
(1995) - et al.
Similarities in the binding sites of the muscarinic receptor and the ionic channel of the nicotinic receptor
Biochemical Pharmacology
(1980) Memantine is a potent blocker of N-methy-D-aspartate (NMDA) receptor channels
European Journal of Pharmacology
(1989)- et al.
Different binding affinities of NMDA receptor channel blockers in various brain regions—indication of NMDA receptor heterogeneity
Neuropharmacology
(1995) - et al.
Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats
European Journal of Pharmacology
(1992) - et al.
Interaction between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease
Trends in Neuroscience
(1990) - et al.
2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA) displaces [3H]AMPA binding in rat striatum
Neuroscience Letters
(1991) - et al.
Glutamate antagonists have different effects on spontaneous locomotor activity in rats
Pharmacology and Biochemistry of Behavior
(1994) - et al.
Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions
Trends in Neuroscience
(1994) - et al.
Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate
European Journal of Pharmacology
(1991)
Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease
European Journal of Pharmacology
(1971)
The effect of dimethylaminoadamantane on neuronal membranes
European Journal of Pharmacology
(1976)
The NMDA antagonist dizocipline (MK-801) reverses haloperidol-induced movement initiation deficits
Behavioral Brain Research
(1990)
Evaluation of amantadine as releasing agent or uptake blocker for [3H]dopamine in rat brain slices
European Journal of Pharmacology
(1972)
Amantadine and D-145, an amantadine derivative, do not effect dopamine sensitive adenyllate cyclase from the caudate-putamen of the rat brain
European Journal of Pharmacology
(1974)
Memantine prevents quinolinic acid-induced hippocampal damage
European Journal of Pharmacology
(1992)
Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel—a human postmortem brain study
European Journal of Pharmacology
(1991)
Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex
European Journal of Pharmacology
(1989)
Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man
Neuroscience Letters
(1995)
Therapeutic brain concentration of the NMDA receptor antagonist amantadine
Neuropharmacology
(1995)
Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex
Neuroscience Letters
(1993)
Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats
European Journal of Pharmacology
(1993)
Antiparkinsonian drugs and invitro excitotoxicity
Brain Research
(1992)
Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative
European Journal of Pharmacology
(1974)
Effects of memantine on the frog neuromuscular junction
European Journal of Pharmacology
(1986)
GABA-ergic drugs block the locomotor stimulant effects of 1,3-dimethyl-5-aminoadamantane (D-145)
Neuropharmacology
(1979)
Pharmacological evidence for the involvement of GABA-ergic system in the locomotor stimulation produced in mice by 1,3-dimethyl-5- aminoadamantane (D-145)
Neuropharmacology
(1978)
Effect of amantadine on chlorpromazine and reserpine-induced behavioral depression in the mouse
Neuroscience and Biobehavioral Reviews
(1988)
Learning deficit induced by chronic intraventricullar infusion of quinolinic acid—protection by MK-801 and memantine
European Journal of Pharmacology
(1996)
Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism
Brain Research
(1994)
Memantine stimulates inositol phosphates production in neurones and nullifies N-methyl-D-aspartate-induced destruction of retinal neurones
Neurochemistry International
(1992)
Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)
Neuropharmacology
(1993)
Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo
Neuropharmacology
(1995)
Evidence that D145 is limbic specific
British Journal of Pharmacology
(1982)
Clinical pharmacokinetics of amantadine hydrochloride
Clinical Pharmacokinetics
(1988)
Amantadine kinetics in healthy young subjects after long-term dosing
Clinical Pharmacokinetics and Therapeutics
(1979)
Amantadine and sparteine inhibit ATP-regulated K-currents in the insulin-secreting beta-cell line
British Journal of Pharmacology
(1991)
The mechanism of amantadine in Parkinsonism: a review
Archives of International Pharmacodynamics
(1975)
Der 3,4-dioxyphenylalanin (=L-dopa) — Effekt bei der Parkinson akinesie
Wien Klinik Wochenschrift
(1961)
Absorption, distribution and excretion of amantadine hydrochloride
Journal of Pharmacology and Experimental Therapeutics
(1965)
Amantadine sulphate in treating Parkinson's disease: Clinical effects, psychometric tests and serum concentrations
Journal of Neurology
(1989)
Studies on the mechanism of action of amantadine
British Journal of Pharmacology
(1976)
Control by asparagine residues of calcium permeability and magnesium blockade in the NMDA receptor
Science
(1992)
The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
Journal of Neural Transmission
(1989)
Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine—t herapeutic advantage against NMDA receptor-mediated neurotoxicity
Journal of Neuroscience
(1992)
The time course of glutamate in the synaptic cleft
Science
(1992)
Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamatan)
Psychopharmacology
(1975)
The 6-hydroxydopamine rotational model for the detection of dopamine agonist activity: reliability of effect from different locations of 6-hydroxydopamine
Journal of Pharmacy and Pharmacology
(1975)
Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine
Journal of Neural Transmission [Parkinson's Disease Section]
(1994)
Glutamate in CNS disorders — a revived target for drug development
Drugs News Perspectives
(1995)
Cited by (344)
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
2022, NeuropharmacologyEffects of preoperative intravenous amantadine sulfate infusion on wake up test duration and postoperative opioid consumption in adolescents undergoing spine corrective surgery
2021, Perioperative Care and Operating Room ManagementClinical benefits and risks of N-methyl-D-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review
2020, Drug and Alcohol DependenceCitation Excerpt :Amantadine’s neuroprotection results from its ability to inhibit glutamatergic NMDAR. However, amantadine blocks the open NMDAR channel, probably, by attenuating the imbalance between dopamine and glutamate (Danysz et al., 1997). If one must disagree that the NMDAR may be central to opioid use disorder, one can also argue that studies had suggested that methadone may attenuate or block the NMDAR (Inturrisi, 2005; Sotgiu et al., 2009; Holtman and Wala, 2007; Chizh et al., 2000), and probably, methadone or buprenorphine solely relies on the NMDAR.
Amantadine exerts anxiolytic like effect in mice: Evidences for the involvement of nitrergic and GABAergic signaling pathways
2020, Behavioural Brain ResearchTargeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia
2020, Neurobiology of Disease
- ∗
Dept. of Pharmacology, Merz + Co., Eckenheimer Landstrasse 100-104, 60318 Frankfurt/Main, Germany. Tel.: (+49)-69-15-03-564; Fax: (+49)-69-59-62- 150
Copyright © 1997 Published by Elsevier Ltd.